Abstract
Background Glycated haemoglobin, or HbA1c, is the main biomarker used to assess long-term glycaemic control in individuals with diabetes, and it correlates with the development of complications. Objective The aim of this article is to provide an overview of HbA1c to understand its role in the treatment of individuals living with diabetes. Topics discussed include recommended treatment targets, methods of measurement, causes of measurement inaccuracy and alternative means available to assess glycaemic control.Discussion HbA1c should not be interpreted in isolation; the measurement accuracy and other parameters, including treatment goals and comorbidities, need to be considered.
| Original language | English |
|---|---|
| Pages (from-to) | 628-632 |
| Number of pages | 5 |
| Journal | Australian Journal of General Practice |
| Volume | 50 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2021 |
Bibliographical note
Publisher Copyright:© The Royal Australian College of General Practitioners 2021
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'HbA1c : more than just a number'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver